PRKACA and hepatocellular carcinoma: A personalized DNAJB1-PRKACA-derived peptide vaccine was designed for a young patient with histologically confirmed FL-HCC (FL-HCC01), who suffered from multiple tumor relapses after receiving an early liver transplant (LTx), due to unresectable FL-HCC not responsive to chemotherapy (Fig. 4a and Supplementary Fig. S4a).